Related Experiment Videos
[Circulating cardiac antigens in animals with experimental myocardial infarct undergoing malaben pharmacotherapy]
Insights
This study shows that elevated heart antigens in the blood indicate myocardial infarction in rats. Malaben treatment reduced these antigens, suggesting a smaller necrotic area and potential diagnostic use for coronary heart disease.
Area of Science:
- Cardiology
- Biochemistry
Context:
- Experimental myocardial infarction in rats.
- Monitoring of heart antigens in blood.
Purpose:
- To investigate the effect of malaben treatment on heart antigen levels during myocardial infarction.
- To evaluate heart antigens as a diagnostic and prognostic marker for coronary heart disease.
Summary:
- Chronic experiments on rats with experimental myocardial infarction revealed elevated blood levels of heart antigens.
- Untreated animals maintained high antigen levels for a month, while malaben treatment significantly decreased antigen concentration and circulation duration.
- This decrease suggests a reduction in myocardial necrosis, supporting the role of heart antigens in diagnosis and prognosis.
Impact:
- Determination of blood heart antigens can serve as a diagnostic criterion for coronary heart disease.
- Blood heart antigen levels may function as a prognostic test for patients undergoing drug therapy for coronary heart disease.
Abstract:
It has been established in chronic experiments on rats that during experimental myocardial infarction, the blood has a complex of heart antigens (up to 250 micrograms/ml). In untreated animals, a high content of heart antigens remains unchanged for a month, slightly diminishing in the second half of the observation period. During malaben treatment, the concentration of heart antigens and duration of their circulation in the blood noticeably decreases which evidences the reduction of the focus of necrosis in the myocardium. It is inferred that determination of the blood content of heart antigens may serve as diagnostic criterion and prognostic test in coronary heart disease subjected to drug therapy.